Votoplam Enters Phase 3 Trial for Early Symptomatic Huntington Disease Novartis investigators are now recruiting for a phase 3 trial to assess the efficacy and safety of votoplam in early symptomatic HD.

@novartis.bsky.social’ phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of #Votoplam (#HTT227) in participants with early symptomatic Huntington disease (HD) is now recruiting.

Read more: https://bit.ly/3NDsFwQ

#RareDisease #ClinicalTrial #HuntingtonDisease #MedSky

My thoughts on the @ptcbio.bsky.social Pivot-HD top line results #HuntingtonsDisease #votoplam ir.ptcbio.com/static-files...